|
1
|
Angervall L, Kindblom LG and Merk C:
Ayxofibrosarcoma: A study of 30 cases. Acta Pathol Microbiol Scand
A. 85A:127–140. 1977.PubMed/NCBI
|
|
2
|
Fletcher CD, Bridge JA, Hogendoorn PC, et
al: WHO classifitation of tumours of soft tissue and bone. Lyon,
IARC Press, 93-94, 2013.
|
|
3
|
Uehara T, Fujiwara T, Takeda K, Kunisada
T, Ozaki T and Udono H: Immunotherapy for bone and soft tissue
sarcomas. Biomed Res Int. 2015(820813)2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tawbi HA, Burgess M, Bolejack V, Van Tine
BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA,
et al: Pembrolizumab in advanced soft-tissue sarcoma and bone
sarcoma (SARC028): A multicentre, two-cohort,
single-arm,open-label, phase 2 trial. Lancet Oncol. 18:1493–1501.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
D'Adamo DR, Anderson SE, Albritton K,
Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H and Maki RG: Phase
II study of doxorubicin and bevacizumab for patients with
metastatic soft-tissue sarcomas. J Clin Oncol. 23:7135–7142.
2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ruihua Xu: Medical Oncology. Bei Jing:
People's Medical publishing house, 549-565, 2014 (In Chinese).
|
|
7
|
Yin QL, Wu D and Yu YY: Progression in
anti-angiogenesis agents for soft tissue sarcoma. Chinese Clinical
Oncol. 22:839–844. 2017.(In Chinese).
|
|
8
|
Sleijfer S, Ray-Coquard I, Papai Z, Le
Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De
Brauwer A, et al: Pazopanib, a muhikinase angiogenesis inhibitor,
in patients with relapsed or refractory advanced soft tissue
sarcoma: A phaseIIstudy from the European organisatiou for research
and treatment of eaneer-sofc tissue and bone sarcoma group (EORTC
study 62043). J Clin Oncol. 27:3126–3132. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
In GK, Hu JS and Tseng WW: Treatment of
abvanced, metastatic soft tissue sarcoma: Latest evidence and
clinical considerations. Ther Adv Med Oncol. 9:533–550.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sarcoma Committee of Chinese Anti-Cancer
Association; Chinese Society of Clinical Oncology. Chinese expert
consensus on diagnosis and treatment of soft tissue sarcomas
(Version 2015). Zhonghua Zhong Liu Za Zhi. 38:310–320.
2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
12
|
Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang
G, Du F, Sun Y, Wu Q, Qu G, et al: Safety and efficacy of
anlotinib, a multikinase angiogenesis inhibitor, in patients with
refractory metastatic soft-tissue sarcoma. Clin Cancer Res 24:
5233-5238.
|
|
13
|
Paoluzzi L, Cacario A, Ghesani M,
Karambelkar A, Rapkiewicz A, Weber J and Rosen G: Response to
anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin
Sarcoma Res. 6(24)2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ben-Ami E, Barysauskas CM, Solomon S,
Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M,
Patel T, et al: Immunotherapy with single agent nivolumab foe
advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Cancer. 123:3285–3290. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
D'Angelo SP, Mahoaey MR, VanTine BA,
Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap
WD, Schwartz GK and Streicher H: Nivolumab with or without
ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two
open-label non-comparative, randomized,phase 2 trials. Lancet
oncol. 19:416–426. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wagner MJ, Ricciotti RW, Mantilla J,
Loggers ET, Pollack SM and Cranmer LD: Response to PD1 inhibition
in conventional chondrosarcoma. J Immunother Cance.
6(94)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Linpeng Zhen, Luping Zhang, Zihan Xu, et
al: Radiation therapy combined with immunological checkpoint
inhibitors and distant effects. Chin J Lung Dis (Electronic
Edition). 11:227–230. 2018.(In Chinese).
|
|
18
|
Zhouguang Hui, Meng Yuan and Yu Men:
Application mechanism of radiotherapy combined with immune
checkpiont inhibitors. Chin J Radiat Oncol. 27:875–879. 2018.(In
Chinese).
|
|
19
|
Wang Q and Li B: Research progress in
PD-1/PD-L1 monoclonal antibody combined with radiotherapy in
treatment of solid tumors. Chin J Radiat Oncol. 25:1375–1378.
2016.(In Chinese).
|
|
20
|
Peng X and Zhou Q: First-line combination
immunotherapy in advanced non-small cell lung cancer. Zhongguo Fei
Ai Za Zhi. 21:924–930. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
21
|
Zhang J, Zhang W, Qian Z, Gao B and Xiang
Y: Tumor vascular normalization improves cancer treatment efficacy.
China Oncology. 26:188–192. 2016.(In Chinese).
|
|
22
|
Xu Y, Zhang L and Jin L: Mechanism of
tumor tolerance mediated hy immune microenvironment and its
targeted therapy. J Int Oncol. 44:594–596. 2017.(In Chinese).
|
|
23
|
Zhang B and Yue H: The mechanisms of
immune microenvironment in cancer development and progression.
Modern Oncol. 23:862–864. 2015.(In Chinese).
|
